The anticonvulsants that are currently available modulate the activity of neuronal receptors and ion channels, which are equally involved in apoptotic pathways. We investigated the hypothesis that gabapentin (GP), an anticonvulsant without effect on glutamate receptors acting as GABA analog, has neuroprotective properties. For comparison, we chose topiramate (TPM), which has been reported to be neuroprotective via AMPA receptors blockade. For this purpose, we used rat cerebellar granule neuron (CGN) cultures and we triggered apoptosis independent of glutamate receptors with staurosporine, a broad-spectrum protein kinase inhibitor. GP at therapeutic range concentration significantly increased cell viability in CGN cultures maintained in physiological KCl concentration and reversed apoptosis induced by staurosporine. Blockade of NMDA or AMPA receptors by MK801 or NBQX, respectively, did not alter GP neuroprotection, which was reversed instead by GABA. In contrast, protective effect of TPM on STS-treated CGN cultures was annihilated by NBQX, and not altered by MK801 or GABA. Treatments with neuroprotective concentrations of GP or TPM did not modify the expression of neuronal cell adhesion molecule or synaptophysin or the morphological aspect of neuronal endings. In summary, we report that GP is neuroprotective through glutamate-receptor independent mechanisms and without alteration of neuronal plasticity markers, which makes it a possible candidate for clinical neuroprotection trials.
Introduction
Apoptotic cell death is implicated in a large variety of neurological diseases, of both acute (stroke, traumatic brain injury) and chronic neurodegenerative (Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease) types, as documented by many studies [1, 2] . The extension of cell loss within the injured nervous system correlates with the degree of resultant neurological deficits, neurological diseases being a leading cause of invalidity,
with consequent low quality of life and high economic costs [3] . The concept of neuroprotection refers to strategies that may result in salvage or recovery of injured nervous tissue [4] and is mainly applicable to apoptotic neuronal death, which in contrast to necrosis takes enough time to allow for intervention.
A vast array of molecules with di erent mechanisms of action were demonstrated to be neuroprotective in cellular and animal models, most of them in excitotoxic experimental paradigms, but none proved effective in humans, largely due to toxic side effects.
Glutamate is the main excitatory neurotransmitter of the brain: glutamate receptors play a crucial role in various physiological functions, operating both rapid excitatory transmission and slow cellular changes involved in memory, neuronal plasticity and development. Excessive glutamate release or dysregulation of glutamate receptors' function or expression may play a role not only in epilepsy but also in cell death associated with neurodegenerative diseases [5] . An as yet unresolved issue is that counteracting glutamate excess in order to protect neurons from excitotoxicity could result in decreased neuronal plasticity and repair.
The available anticonvulsants modulate the activity of neuronal receptors and ion channels, mostly linked to glutamate neurotransmission, which are equally involved in apoptotic pathways. Many of these drugs were shown to be protective against neurodegeneration in epilepsy models but also, in some studies, against apoptosis triggered by ischemia, excess excitatory neurotransmitter release, or lethal increase in intracellular Ca 2+ concentration [6] , and their neuroprotective potential was insufficiently explored by clinical trials [7] .
Gabapentin (GP) is an antiepileptic drug structurally related to gamma-aminobutyric acid (GABA), for which different mechanisms of action have been suggested, such as an increase of GABA-ergic inhibition and effects on ion-gated (Na + , Ca 2+ ) and ligand-gated (GABA and glutamate receptors) ion channels [8] . Recently, binding of the compound to the voltage-gated Ca 2+ channel α2-δ1 auxiliary subunit with selective inhibitory e ect was demonstrated [9, 10] . GP was not extensively tested as a neuroprotective agent, the few existing studies have produced contradictory results, suggesting both efficiency [11] [12] [13] [14] [15] or ine ciency [16, 17] having being reported [8] . A bulk of coherent evidence supports the protective role of TPM in both epilepsy [18, 19] and other models of neurodegeneration [6, 20, 21] .
In order to evaluate whether GP has antiapoptotic properties, we chose to explore the e ects of this drug in cerebellar granule neurons (CGN) cultures where apoptosis was triggered by staurosporine (STS). CGN cultures represent a well described and valuable model to test molecules for neuroprotection [22] and STS is a broad-spectrum protein kinase inhibitor widely used to trigger apoptosis in all cell types, including neurons [23] . We considered this hypothesis attractive due to the fact that GP does not act primarily by glutamate receptor blockade, and it is therefore unlikely that it would a ect neuronal plasticity. Aside from GP we studied the effects of TPM (which has been demonstrated to be protective due to AMPA-kainate blockade activity [24] and shows concomitant inhibition of fast Na + and high-voltage activated Ca 2+ conduction [21] ) in the same model system for comparison. In addition, we used GABA as a hyperpolarizing agent and NMDA and AMPA/kainate receptor antagonists, to identify whether the protection mechanisms were receptor-mediated. We also tested effects of GP and TPM on the expression of neuronal cell adhesion molecule (NCAM) and synaptophysin (SP), proteins which are important for neuronal plasticity [25, 26] . Primary rat CGN cultures were prepared as previously described [27] and grown in all The control cells were exposed to vehicle (DMSO) in growth medium for 6 hours. At least 3 different experiments were run for each experimental situation. The concentrations of GP and TPM were selected to be close to the plasma concentrations of these drugs in patients efficiently treated for epilepsy [28, 29] and concentrations of the receptor agonist GABA, NMDA receptor antagonist MK801 and AMPA receptor antagonist NBQX were selected to be in the range of their maximum activity.
Methods and materials

The concentration of STS was chosen based
on a previous study [27] in order to have a partial and potentially reversible induction of apoptosis in CGN cultures.
Assessment of cell death Cell viability
Cell viability was assessed by MTT 
Detection of apoptotic cells
Statistical analysis
The data are presented as mean ± standard error of the mean (S.E.M.). The statistical analysis of cell death assays results was performed by ANOVA followed by Fisher's post-hoc test, using SPSS 12.0 statistical software. A value of p < 0.05 was considered statistically significant.
Results
Gabapentin increases cell viability in CGN cultures maintained in physiological KCl concentration
Taking advantage of the fact that CGN express both ionotropic glutamate and GABA A receptors [31] and that a proportion of these neurons die by apoptosis when cultures are maintained in physiological KCl concentration 
Staurosporine triggers apoptosis in CGN cultures
CGN cultures were exposed to STS, a wellcharacterized inducer of apoptosis in neurons [23, 33] . We explored cell viability in CGN cultures related to di erent STS concentrations over 24
hours in a previous study [27] . In this study we Gabapentin and topiramate protect cerebellar granule neurons against staurosporine-triggered apoptosis through di erent mechanisms
To explore whether GP and TPM are protective against STS-triggered apoptosis, we further determined cell viability in CGN cultures treated with STS and the hypothesized neuroprotective agent in combination. As Figure 1 . Study of effects of antiepileptic drugs and receptor operators on cell viability in staurosporine-triggered cell death. Rat cerebellar granule neuron cultures were exposed in growth medium for 6 h to the various treatments indicated by abbreviations. Cell viability estimated by MTT assay was calculated in percentages of cell viability in control cells, which were exposed to vehicle (DMSO) in growth medium for 6 h. An average of optical density of all control wells from all experiments was taken as 100% (n = 78). TPM = topiramate (30 μM), GP = gabapentin (30 μM), GABA = gamma-aminobutyric acid (2 mM), MK801 = 5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine) maleate, NMDA receptor antagonist (10 μM), NBQX = 6-nitro-7-sulfamoylbenzo(f )quinoxaline-2,3-dione, AMPA receptor antagonist (100 μM), STS = staurosporine (1 μM). Error bars indicate standard error mean (SEM). Statistical analysis of the results was carried out using ANOVA followed by Fisher's post-hoc test. ##, p < 0.01; ###, p < 0.001 (24 ≤ n ≤ 78) mark the statistical significance in cell viability as compared to control values. *, p < 0.05; **, p < 0.01; ***, p<0.001 (9 ≤ n ≤ 78) mark the statistical significance in cell viability for cells treated with STS + cotreatment as compared to cells treated with STS alone. §, p < 0.05 Even though it is well-documented that STS triggers apoptosis independent of glutamate and GABA receptors [34] , considering that endogenous glutamate is released in CGN cultures and that these cultures are sensitive to changes in receptor-operated intracellular ionic concentrations [31] and that the main mechanism of TPM neuroprotection is the blockade of AMPA receptors [24] , we tested whether we can reverse the protective effect of GP and TPM by GABA or by glutamate ionotropic receptor antagonists.
In these conditions we found that GABA 
Discussion
Antiepileptic drugs have been used extensively in clinical practice and it has been suggested that they might be neuroprotective by a large array of experimental studies [6] . Unlike TPM, for which neuroprotection in conditions linked to both epilepsy and ischemia was demonstrated [18] [19] [20] [21] , studies regarding GP neuroprotection are scarce and contradictory [15, 17] . Together with pregabalin and vigabatrin, GP belongs to the GABA analog group of anticonvulsants and it is a well-tolerated drug in most patients, with a mild side-effect profile. For GP, the main antiepileptic mechanism of action is binding to the voltage-gated Ca 2+ channel α2-δ1 auxiliary subunit with selective inhibition of the channel [10] . Considering that neuroprotective drugs like TPM, which block ionotropic glutamate receptors [24] , could interfere with neuronal plasticity, which is also regulated through glutamate neurotransmission [35] , we considered it important to explore whether an anticonvulsant with a di erent mechanism of action, like GP, has neuroprotective properties.
We chose to explore the effects of GP in an experimental paradigm suitable to the detection of apoptosis and neuroprotection. Rat CGN cultures represent a well-described and valuable model to the study of the mechanisms of neurodegeneration and test molecules for neuroprotection [22] . These cultures contain glutamatergic cells which express ionotropic glutamate and GABA A receptors [31] and are characterized by spontaneous synapse formation and electrical activity when CGN are cultured in physiological medium [36] . In CGN cultures a proportion of naturally occurring apoptosis is documented 3-5 days after plating, which can be rescued by elevated KCl concentration through the activation of voltage-gated Ca 2+ channels and depolarization [32] .
STS is a broad-spectrum protein kinase inhibitor widely used to trigger apoptosis in all cell types including neurons [23, 33, 37] . We used STS to trigger apoptosis because this model has well-characterized mechanisms of cell death (release of cytochrome c, increase in reactive oxygen species, calcium dysregulation and caspase activation) and is not operated primarily by glutamate receptors [34] . We also considered the fact that in CGN cultures, glutamate is endogenously released by granule cells in a physiological concentration at synapse level [31] , which can interfere with cell survival, and therefore we used glutamate ionotropic receptor antagonists to explore effects of glutamate release. It is nonetheless possible for dying neurons with altered membranes to release excess non-synaptic glutamate in these cultures. In our experiments we also used GABA, which was shown to protect CGN from death triggered by excessive endogenous glutamatergic stimulation [38] .
We first examined the effects of GP and TPM on CGN cultured in physiological medium and we showed that GP was able to increase cell viability, while TPM lacked this effect.
Once NBQX and MK801 were also unable to significantly increase cell viability in this paradigm, we concluded that the GP effect was glutamate receptor independent. Moreover, from other studies it could have been predicted that blockade of glutamate receptors in CGN cultured in physiological medium would not result in neuroprotection [36, 38] .
Next, we investigated the neuroprotective capabilities of GP and TPM in STS-induced cell death and we found that both anticonvulsants were able to significantly rescue neurons from apoptosis. As expected, and due to the fact once GP is an inhibitor and GABA an activator of these channels [10] .
Neuroprotection of GP was insensitive to the blockade of glutamate ionotropic receptors, in contrast to neuroprotection of TPM, which was reversed by AMPA-receptor antagonist NBQX.
NBQX itself was not able to rescue cells from apoptosis, suggesting that neuroprotection of TPM is mediated through AMPA-receptors but not by a similar mechanism such as NBQX.
This result is in conflict with studies which demonstrated neuroprotection with TPM in ischemia models [21, 24] . However, a different apoptosis inducer was used in these studies [21, 24] , which does not primarily operate on glutamate receptors. 
